Latest News
BGF has backed Sentric Music with an initial investment of GBP3 million to help accelerate the publisher’s international expansion plans, as well as forming a partnership to fund future acquisitions.
An independent company with up to GBP2.5 billion in capital for long-term equity investments, BGF is backed by five of the UK’s main banking groups – Barclays, HSBC, Lloyds, RBS and Standard Chartered.
Liverpool-headquartered Sentric Music works with more than 90,000 songwriters, providing music publishing, licensing opportunities and royalty collection services.
In addition to expanding internationally, Sentric plans to use BGF’s investment to continue to develop its products,
Advicenne, a late-stage biopharmaceutical company focused on the development of paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases, has closed a EUR16 million financing round.
The fundraising was led by IRDI SORIDEC Gestion, Cemag Invest and MI Care alongside existing investors InnoBio (Bpifrance) and IXO Private Equity together with private individuals.
Advicenne plans to use these funds to advance its late-stage pipeline in nephrology and neurology, including: the completion of the Phase III development of ADV7103, which is targeting a renal tubulopathy, an orphan indication. ADV7103 is currently in a pivotal phase III trial in
Private equity firm Beaubridge is leading a GBP2.5 million investment in Florismart, an online marketplace connecting florists throughout Europe.
Beaubridge has chosen CoInvestor to make this EIS investment opportunity available to investors to access directly and invest in online.
The Florismart platform is designed to allow florists to come together to create a competitive marketplace between suppliers resulting in greater product choice and improved prices for the florists with all their purchases delivered direct to their premises overnight. Savings can be as high as 20 per cent over the tradition supply model with flowers delivered direct from the grower
KKR and CDPQ have teamed with employees of USI Insurance Services to acquire the US insurance brokerage and consulting firm.
As partners with equal ownership, KKR and CDPQ will acquire USI from Onex Corporation and its affiliates in a transaction that values USI at USD4.3 billion.
With more than 4,400 professionals operating out of 140 local offices throughout the US, USI delivers property and casualty, employee benefits, personal risk and retirement solutions.
The investment will primarily be made through KKR and CDPQ’s core private equity partnership which includes funds from KKR’s balance sheet and from CDPQ’s pool of
Law firm Goodwin has appointed Samantha Lake Coghlan and Paul Lyons as co-chairs of the firm’s London office with immediate effect.
They succeed David Evans, who will continue as chair of Goodwin’s European offices, providing support to the heads of the firm’s London, Frankfurt and Paris offices in the areas of integration, culture, collaboration and strategic growth.
“David has done an exceptional job in driving the strategic growth of our London office over the past five years, and I am confident that under Sam and Paul’s stewardship, Goodwin London will go from strength to strength,” says David Hashmall, chairman
Italian private equity firm Progressio SGR has sold its majority stake in the Duplomatic group, a Milan-headquartered provider of hydraulic components and systems.
In fewer than four years of Progressio ownership, Duplomatic increased both revenues and EBITDA by approximately 50 per cent each. The enterprise value at closing was EUR69 million.
Progressio acquired a majority (86 per cent) stake in Duplomatic Oleodinamica, the operating holding, in April 2013 from Axa Private Equity (the remaining 14 per cent was held by the management team). At the time of the acquisition, the group also held US company Continental Hydraulics, and had
MultiX, a provider of spectroscopic x-ray imaging for airport security and non-destructive testing applications, has raised EUR3.5 million in a new financing round led by with its long-standing investors and two newcomers – Omnes Capital and H3C (private investor).
MultiX was founded in October 2010 by Jacques Doremus and Patrick Radisson with the support of the French Atomic Energy Commission (CEA) and Thales.
The company – whose two founders are from the Thales Group – provides its integrator clients with detection subsystems that allow for efficient baggage security checks, reduced operating costs for airports and passenger comfort, making it
HIG Bayside Capital (Bayside), the distressed debt and special situation affiliate of private equity firm HIG Capital, is to sell the Beauty Bell Chain (Bodybell) following a restructuring of the company’s operations, to Douglas, a European retailer in the selective beauty market.
Bodybell, founded in the 1970s, is a distributor of perfumery and household products in Spain. The company’s product range comprises selective and mass-market beauty as well as personal and home care products.
Bayside acquired control of Bodybell through a complex financial restructuring that resulted in a debt-for-equity swap in 2015. Bayside also underwrote a new money facility
TTV Capital has held the final close of TTV Fund IV at USD93 million, well over two times the size of Fund III.
TTV added several new limited partners, including a sovereign wealth fund, endowments, foundations, family offices, Invest Georgia, and strategic investors.
“The TTV team is thrilled to have Fund IV fund raising wrapped up so we can focus all of our attention on building out the rest of the portfolio and helping all of our companies achieve notable revenue growth and scale,” says Gardiner Garrard, co-founder and a managing partner of TTV.
To date the fund
Pivotal bioVenture Partners has held the closing of Pivotal bioVenture Partners Fund I, raising over USD300 million to invest in early stage biotechnology companies.
Pivotal bioVenture Partners, funded by the Nan Fung Group, is led by Dr Tracy Saxton and Vincent Cheung.
Pivotal’s investment strategy is centred on identifying companies developing groundbreaking, differentiated science from discovery to early clinical development with the potential to deliver transformative therapies.
“This is an amazing period of innovation in medicine as our knowledge of life sciences is constantly evolving,” says Saxton. “Pivotal will invest in biotechnology companies with strong teams and differentiated
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
